Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story
Becton Dickinson (NYSE:BDX) has launched the Elyra Thulium Fiber Laser System for kidney stone procedures, expanding its urologic stone management portfolio in the United States. This launch tests the company's execution capabilities amidst a mixed stock performance, a microbiology pouch recall, and new leadership in BD Interventional. Investors will be watching the adoption rate of the Elyra system and the company's ability to maintain product reliability and address its debt levels.
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market
In uncertain market conditions, Dividend Kings—stocks that have increased dividends for at least 50 consecutive years—are often favored. The article argues that AbbVie (NYSE: ABBV) stands out among these for its stable business, attractive dividend yield of over 3.2%, reasonable valuation (14.7x forward earnings), and strong growth prospects, particularly after successfully navigating the Humira patent cliff with its successor drugs. While other Dividend Kings may have shortcomings in yield, valuation, or growth, AbbVie is presented as a balanced choice for income, value, and long-term growth investors.
Opinion: AbbVie Is the Best Dividend King to Buy in an Increasingly Uncertain Market
The article suggests AbbVie (NYSE: ABBV) as the top "Dividend King" pick for investors during uncertain market conditions. It highlights AbbVie's stable business, attractive dividend yield (over 3.2%), consistent dividend increases for 53 years, and a favorable valuation with a forward P/E ratio of 14.7. The company's successful navigation of the Humira patent cliff and strong growth prospects with successors like Rinvoq and Skyrizi are also emphasized.
Abbott Laboratories (ABT) Slid Due To Its Nutrition Segment’s Sensitivity to Consumer Spending Momentum
Abbott Laboratories (ABT) underperformed in Q1 2026 due to disappointing Q4 2025 financial results and soft 2026 sales guidance, primarily impacted by its nutrition business's sensitivity to consumer spending trends. This company-specific weakness was exacerbated by a general decline in investor sentiment across the medical device industry. Despite this, 71 hedge funds held ABT at the end of Q4 2025, an increase from the previous quarter.
How syringe-maker BD is using AI to stay sharp
Becton Dickinson (BD), a leading medical device company, is integrating AI and automation with "lean manufacturing" principles to boost efficiency and innovation. CEO Tom Polen has implemented the BD Excellence program, which combines Toyota's continuous improvement methods with AI vision systems and robotics to optimize production and reduce waste. The strategy aims to empower employees, enhance productivity, and reposition BD for future growth beyond traditional medical devices into areas like AI sensors and regenerative medicine.
Abbott Laboratories, Coca-Cola, and Walmart: Top Recession-Proof Stocks for 2026 - News and Statistics
Amid persistent concerns about a potential recession and rising inflation, analysts recommend Abbott Laboratories as a strong recession-proof stock. Abbott Laboratories boasts a broad portfolio of healthcare products, a leadership position in baby formula, and a strong medical device business, ensuring consistent demand regardless of economic conditions. The company is also recognized as a Dividend King, having increased its dividend for 54 consecutive years, offering investors a reliable income stream during economic downturns.
Stroke warning signs: HCA Healthcare stroke survivors share why it’s important to B.E. F.A.S.T.
During Stroke Awareness Month, HCA Healthcare emphasizes the critical importance of recognizing stroke symptoms early by using the B.E. F.A.S.T. acronym. HCA Healthcare has significantly reduced door-to-needle times for stroke treatment and partners with the American Heart Association to improve prevention and care. The article shares inspiring stories of several stroke survivors, including an ER nurse, a collegiate athlete, a father, a doctoral student, and a CNA student, all of whom benefited from quick action and highlight the diverse circumstances in which strokes can occur.
Mint patch pump launch target set for Q2 2027 by Beta Bionics (NASDAQ: BBNX)
Beta Bionics (NASDAQ: BBNX) has announced that it targets the full commercialization of Mint, its patch insulin pump, by the end of Q2 2027, subject to FDA regulatory clearance. The updated timeline is based on initial FDA responses and progress in scaling manufacturing, anticipating capacity to meet launch demand. Mint is designed to offer a 200-unit insulin reservoir, three days of wear, smartphone control, and compatibility with leading continuous glucose monitors and Beta Bionics’ adaptive dosing algorithm.
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
Beta Bionics announced an updated commercialization timeline for its Mint™ patch pump, expecting full commercialization by the end of Q2 2027, pending FDA regulatory clearance. The timeline is based on initial FDA responses and progress in manufacturing scaling. Mint is designed to be compatible with Beta Bionics’ adaptive insulin dosing algorithm, offering innovative features for people with diabetes.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. stock exhibited a strong performance on a recent trading day, closing higher and outperforming its competitors. The stock also surpassed the S&P 500 in daily gains.
Long term debt to total equity ratio of Abbott Laboratories – BVL:ABTUS
This article provides financial data for Abbott Laboratories (ABTUS) on the Lima Stock Exchange, specifically focusing on its long-term debt to total equity ratio. It details the period, value, and change in this ratio. The content appears to be a snapshot from a financial data platform, likely TradingView, presenting a specific financial metric for the company.
Buying pulsed field ablation systems: What hospitals should know
The article discusses factors hospitals should consider when purchasing pulsed field ablation systems due to the crowded market. It lists several companies offering these systems, including Boston Scientific, Abbott, Medtronic, Johnson & Johnson MedTech, and Kardium Inc. The piece is part of a series covering medical devices.
AbbVie stock (US00287Y1091): focus on immunology pipeline after latest data update
AbbVie Inc. is garnering renewed investor attention due to fresh clinical data from its immunology portfolio and the continued emphasis on newer drugs like Skyrizi and Rinvoq, which are intended to offset declining revenue from Humira. The company is actively diversifying its revenue streams through acquisitions and an extensive R&D pipeline in key therapeutic areas like immunology, oncology, neuroscience, and aesthetics. Investors are closely monitoring how effectively AbbVie can navigate the transition from its reliance on Humira and maintain growth amidst increasing competition and evolving market dynamics.
Abbott Laboratories stock (US0028241000): diabetes business and latest earnings in focus
Abbott Laboratories is under close observation following its Q1 2026 results and the performance of its FreeStyle Libre glucose monitoring system, a key growth driver. The diversified healthcare company, which focuses on diagnostics, medical devices, nutrition, and established pharmaceuticals, confirmed its 2026 earnings guidance. The company's strong position in chronic disease management and technological innovation, particularly with FreeStyle Libre, continues to be a focal point for investors.
How Investors May Respond To Becton Dickinson (BDX) Loss, Recall And New Interventional Leadership
Becton, Dickinson and Company (BDX) reported a Q2 net loss of US$311 million despite sales of US$4,714 million, while also affirming full-year GAAP revenue growth guidance and appointing Peter Menziuso to lead BD Interventional. The company's investment narrative now focuses on executing in higher growth franchises like BD Interventional and addressing regulatory and quality pressures highlighted by a recent microbiology pouch recall. Despite these challenges, an expanded infection-prevention partnership and solid operational growth initiatives aim to stabilize earnings, though investors are urged to consider the impact of ongoing quality scrutiny on long-term growth.
Abbott Laboratories stock (US0028241000): investors eye upcoming Q4 2025 earnings call and biosimilar expansion
Abbott Laboratories is preparing for its Q4 2025 earnings call on January 22, 2026, and investors are closely watching its biosimilar strategy for emerging markets growth. The company, a diversified healthcare leader in medical devices, diagnostics, and nutrition, also sees mixed institutional investor activity. Analysts are moderating price targets while maintaining buy ratings, underscoring both growth potential and market uncertainties.
10 Best Stocks to Buy According to Goldman Sachs “Conviction List”
This article identifies 10 top stocks from Goldman Sachs' "Conviction List," screened by short interest as a percentage of float. Goldman Sachs' list highlights compelling investment opportunities, and when combined with low short interest, it suggests strong institutional backing with limited bearish sentiment. The article details the first two stocks on the list: DoorDash, Inc. (NASDAQ:DASH) and UnitedHealth Group Incorporated (NYSE:UNH), outlining Goldman's rationale and recent financial performance for each.
Abbott's Biosimilar Push to Help Sustain EPD Growth Momentum
Abbott's Established Pharmaceuticals Division (EPD) has consistently driven growth, with biosimilars identified as a key pillar for future expansion. The company's strategy involves leveraging partnerships and its broad presence in emerging markets to commercialize biosimilars in oncology, women's health, and respiratory diseases. Despite recent stock performance challenges, Abbott aims to sustain EPD's growth momentum through these initiatives.
Abbott Laboratories stock (US0028241000): steady medical devices player after latest quarterly updat
Abbott Laboratories recently released its first-quarter 2025 results and updated its guidance, highlighting the continued importance of medical devices and diagnostics. The company's core business model spans medical devices, diagnostics, nutrition, and established pharmaceuticals, with key drivers including glucose monitoring systems and cardiovascular products. Its market position is strong due to innovation and diverse offerings, but it faces challenges from competition, regulatory pressures, and supply chain dynamics, making it a closely watched stock for US investors seeking exposure to the healthcare sector.
Worker says Abbott fired him over a chat his coworker started
A former Abbott Laboratories worker, Ryan Lisowski, is suing the company, alleging he was fired over a Teams chat started by a coworker, Abeygail Steele, just hours after he reported a potential product safety concern to the FDA. The lawsuit claims Abbott applied unequal scrutiny to Lisowski compared to Steele and that his termination on February 23, 2026, was a culmination of events including alleged gender bias and retaliation for reporting a baby formula contamination issue. Lisowski had been suspended for over a year following the initial HR questioning.
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $109
Wells Fargo has reiterated its Buy rating for Abbott Laboratories (ABT.US), maintaining a target price of $109. This continued positive outlook suggests the firm sees strong potential in the company's stock.
Has The Recent Slide In Abbott Laboratories (ABT) Opened Up A Valuation Opportunity?
Abbott Laboratories (ABT) has experienced a significant slide in its stock price, dropping 29.2% year-to-date and 33.8% over the past year, which has opened up a potential valuation opportunity. According to a Discounted Cash Flow (DCF) analysis, the stock trades at approximately a 35.4% discount to its estimated intrinsic value of $136.08 per share. The company's P/E ratio is also favorable, trading at 24.49x, which is in line with the industry average and below its peer group, suggesting it is undervalued based on earnings as well.
Silver Economy Investing: Why the Healthcare Giants Are in Focus
The article discusses the "Silver Economy," highlighting how the rapidly aging global population is creating significant growth opportunities in the healthcare sector. It emphasizes how major healthcare companies like Eli Lilly, Tandem Diabetes Care, Intuitive Surgical, and ResMed are capitalizing on this demographic shift through innovation in areas such as obesity, diabetes, robotic surgery, and sleep health. The piece also details specific initiatives by these companies and outlines the financial resilience of the healthcare sector as an investment.
Shareholders Will Be Pleased With The Quality of Becton Dickinson's (NYSE:BDX) Earnings
Becton Dickinson's recent earnings report, despite a subdued stock price reaction, indicates underlying strength. The company's profits were reduced by US$1.3 billion due to unusual items, which are generally non-recurring, suggesting potential for increased profit in the future if these expenses subside. Becton Dickinson has also shown consistent earnings per share growth of 5.7% annually over the last three years.
Abbott Laboratories stock outperforms competitors on strong trading day
Abbott Laboratories (ABT) stock gained 1.04% on Tuesday, closing at $88.82, despite a general market downturn where the S&P 500 and Dow Jones Industrial Average both fell. This marks the second consecutive day of gains for Abbott Laboratories, showcasing its outperformance relative to the broader market.
Wells Fargo Maintains Abbott Laboratories(ABT.US) With Buy Rating, Maintains Target Price $109
Wells Fargo has reiterated its Buy rating for Abbott Laboratories (ABT.US) and maintained its target price at $109. This continued endorsement suggests the firm's confidence in Abbott's financial performance and future prospects. Investors may view this as a positive signal regarding the company's stock value.
Press Release: Avantor(R) Announces Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory
Avantor has announced the appointment of Gerard (Jerry) Porreca as Executive Vice President, Quality and Regulatory, effective June 10, 2024. In this role, Porreca will oversee Avantor's global quality assurance, quality control, regulatory affairs, and environmental, health, and safety organizations. His appointment aims to enhance Avantor's commitment to quality and regulatory compliance in its high-performance product and solutions portfolio.
Abbott Spinal Cord Stimulator Problems Resulted in Severe Paralysis: Lawsuit
A new lawsuit alleges that Abbott's Proclaim Plus 5 spinal cord stimulator malfunctioned, causing the patient to suffer repeated electric shocks, leading to progressive loss of mobility and eventual paralysis from the waist down. The plaintiff, Ray Lavigne, claims the device was ineffective from the start and that Abbott continued to reprogram it despite warnings, ultimately requiring surgical removal. The lawsuit also names the U.S. Food and Drug Administration, arguing the implant should not have been approved for the market.
Scott R. Ward, ex-Medtronic leader, joins Merit Medical board
Merit Medical Systems (NASDAQ: MMSI) announced that shareholders elected Scott R. Ward to its Board of Directors for a three-year term at their annual meeting on May 19, 2026. Ward, an executive with over 40 years of experience in the healthcare and medical device industry, including senior roles at Medtronic and as CEO of Cardiovascular Systems, will serve on the Board’s Governance and Sustainability and Finance and Operating Committees. This appointment is expected to provide valuable strategic insight and support the company's long-term growth and innovation goals.
Exact Sciences Corp stock (US30063P1057): acquisition plans stir debate around growth and dilution
Exact Sciences Corp is set to acquire Abbott’s molecular diagnostics unit, a move that will expand its testing portfolio to include infectious disease and genetic testing alongside its current cancer diagnostics. While this acquisition broadens market reach and leverages existing infrastructure, it also introduces near-term earnings dilution and integration risks. Investors will be closely watching how the company manages these challenges and ultimately realizes the synergies from this strategic expansion.
Resmed, Oura partner on sleep health education, care
Resmed and Oura have announced a partnership to expand access to sleep health education and care, aiming to help individuals better understand and improve their sleep. The collaboration will allow Oura Ring users with signs of nighttime breathing disturbances to access Resmed's resources, including educational materials, sleep assessments, and connections to healthcare providers. This initiative seeks to bridge the awareness gap regarding sleep disorders like obstructive sleep apnea (OSA) and encourage users to seek clinical evaluation.
Abbott Laboratories stock (US0028241000): steady momentum after latest earnings and diabetes tech pu
Abbott Laboratories has shown solid quarterly results and is expanding its diabetes technology portfolio, specifically with its FreeStyle Libre continuous glucose monitoring platform, while the stock maintains stability in a volatile healthcare market. The company operates across medical devices, diagnostics, nutrition, and established pharmaceuticals, with a focus on targeted innovation in chronic disease management and maintaining essential medical needs. This diversified approach positions Abbott as a significant player for US investors looking at long-term healthcare trends and stability.
Virax Biolabs Shares Jumping Again Ahead of Nasdaq Open
Virax Biolabs (NASDAQ: VRAX) shares surged over 53% on Monday and continued to climb in premarket trading on Tuesday, driven by a recent ownership filing and a sponsored RedChip TV appearance. Despite the rally, the thinly traded diagnostics micro-cap remains a penny stock, trading well under $1, and faces risks including potential dilution and the need for new operational updates or clinical data to sustain the momentum. The company is developing T-cell-based technology for immune response tracking, particularly for Long COVID, and is preparing for a U.S. lab-developed test (LDT) launch.
What Insulet (PODD)'s Buybacks, Raised Guidance and Riyadh Hub Mean For Shareholders
Insulet Corporation recently reported strong Q1 results with $761.7 million in revenue and $91.1 million in net income, confirmed upgraded 2026 revenue growth guidance, completed a significant share repurchase, and established a regional headquarters in Riyadh. These moves aim to strengthen the company's financial position, signal confidence in its growth trajectory, and expand its reach into international diabetes markets, particularly focusing on recurring revenue from its Omnipod franchise. The success of the Riyadh hub will be crucial for its international expansion strategy.
Has The Recent Slide In Abbott Laboratories (ABT) Opened Up A Valuation Opportunity?
Abbott Laboratories (ABT) stock has seen a significant decline over the past year, but a recent analysis by Simply Wall St suggests it may now be undervalued. Using a Discounted Cash Flow (DCF) model and Price-to-Earnings (P/E) ratio comparison, the article indicates that ABT could be trading at a substantial discount to its intrinsic value. Investors are encouraged to explore different valuation narratives to form their own conclusions about the stock's potential.
BioCardia Reports Promising CardiAMP Cell Therapy Data in Q1 2026 Conference Call
BioCardia discussed positive results for its CardiAMP Cell Therapy for ischemic heart failure during its Q1 2026 conference call. Blinded echocardiography data from the CardiAMP Heart Failure trial, analyzed by Yale University, showed treated patients maintained stable heart volumes, unlike control subjects. The therapy, which has FDA breakthrough designation and Medicare reimbursement, showed statistically significant benefits in a subgroup with elevated heart stress biomarkers, aligning with a composite endpoint for improved long-term outcomes.
Baxter Board Size Reset Puts Governance Changes In Focus For Investors
Baxter International (NYSE:BAX) recently received shareholder approval to amend its certificate of incorporation and bylaws, adjusting the framework for its board size to between seven and twelve directors. This governance change is viewed as a tool to reshape oversight and potentially bring in fresh expertise, especially in light of the company's weak share performance over the past five years. Investors are now watching for future announcements regarding new director appointments, committee reshuffles, or changes in capital allocation policies to assess how this flexibility will be utilized to address operational and financial challenges.
Abbott Laboratories Insiders Added US$4.23m Of Stock To Their Holdings
Insiders at Abbott Laboratories have significantly increased their stock holdings over the past year, purchasing US$4.23 million worth of shares. This indicates a growing optimism about the company's future prospects, especially given that some purchases were made at prices above the current market value. The strong insider ownership of 0.5% (worth US$722 million) further suggests that management's incentives are well-aligned with shareholders.
ABT Technical Analysis | Trend, Signals & Chart Patterns | ABBOTT LABORATORIES (NYSE:ABT)
This article provides a technical analysis of Abbott Laboratories (NYSE:ABT), giving it an overall technical rating of 0 out of 10. The analysis indicates negative trends in both the short and long term, with the stock performing poorly compared to its peers and the broader market. Key aspects like support and resistance levels, technical indicator signals, and chart patterns are detailed, suggesting it's better to avoid buying ABT due to its current performance and volatile setup.
J&J Has 'No Intention' of Giving Up IVL Market Leadership
Johnson & Johnson's subsidiary, Shockwave Medical, is asserting its continued dominance in the Intravascular Lithotripsy (IVL) market with the global launch of its fifth-generation C2 Aero system. Despite increasing competition from other major medical device companies, Shockwave's Chief Medical Officer, Nick West, emphasizes their commitment to market leadership, citing extensive clinical evidence, a robust reimbursement framework, and continuous R&D with plans for annual product launches. The company differentiates itself by defining true IVL as energy-based and focusing on enhanced deliverability and patient outcomes, even exploring new applications in carotid and structural heart diseases.
DexCom Inc. stock outperforms competitors on strong trading day
DexCom Inc. (DXCM) stock saw a strong trading day, rising 1.34% to $127.00, outperforming both its industry competitors and the broader market indices like the S&P 500 and Dow Jones Industrial Average. Despite the positive daily performance, the stock remains below its 52-week high, having fallen 2.87% over the last five days.
Boston Scientific Corp Stock (BSX) Closed Up by 5.88% on May 18: Facts Behind the Movement
Boston Scientific Corp (BSX) stock closed up by 5.88% on May 18, driven by a strategic $1.5 billion investment in MiRus LLC, including an option to acquire its TAVR business. Further boosting investor confidence, the company initiated a $2 billion accelerated share repurchase agreement following strong Q1 2026 financial results that surpassed expectations. These actions, coupled with reaffirmed "Buy" or "Outperform" ratings from analysts, contributed to the significant upward movement despite some technical indicators suggesting caution.
Boston Scientific Bets on Growth Through Strategic M&A Deals
Boston Scientific is focusing on strategic mergers and acquisitions to drive growth, expand into new areas, and strengthen its market position, exemplified by recent acquisitions in urology and pain management. The company also announced a definitive agreement to acquire Penumbra to enter fast-growing vascular segments. Meanwhile, peers like Abbott Laboratories and Medtronic are also pursuing significant M&A activities to expand their portfolios and market reach.
Abbott Laboratories Stock (ABT) Moved Up by 3.04% on May 18: What Investors Need To Know
Abbott Laboratories (ABT) stock increased by 3.04% on May 18, driven by positive Q1 2026 financial results that surpassed analyst estimates and reaffirmed full-year guidance. The recent $23 billion acquisition of Exact Sciences is expected to significantly strengthen its position in the cancer diagnostics market, contributing to investor confidence alongside strong performance in its Medical Devices segment and consistent shareholder returns. Despite technical indicators showing mixed signals and some analyst concerns about dilution and organic growth, institutional investors have increased their holdings, and the consensus remains a "Buy."
Intuitive Surgical Inc Stock (ISRG) Moved Up by 3.76% on May 18: A Full Analysis
Intuitive Surgical Inc. (ISRG) stock increased by 3.76% on May 18th, driven by strong Q1 2026 financial results, which reported $2.77 billion in revenue and a 23% year-over-year increase. The company also raised its 2026 procedure guidance due to the success of its da Vinci 5 platform. Analysts maintain a "Moderate Buy" rating with a consensus price target of $583.45, reflecting positive market sentiment despite some technical indicators suggesting caution.
ABT Stock Price and Chart — NYSE:ABT
This page provides a comprehensive overview of Abbott Laboratories (ABT) stock performance, financial metrics, and analyst insights. It details key statistics like market capitalization, dividend yield, P/E ratio, and revenue, along with historical price movements and future earnings expectations. The article also includes various trading ideas and technical analyses from the TradingView community, alongside information on the company's segments and ETFs holding its stock.
Abbott Laboratories (ABT) is attracting investor attention: Here is what you should know
This article focuses on Abbott Laboratories (ABT) and why it's gaining investor attention. It suggests that recent price changes and financial metrics are key factors attracting interest. The article is likely to delve into specific financial details and market sentiment surrounding ABT.
Abbott Laboratories stock outperforms competitors on strong trading day
Abbott Laboratories (ABT) stock rallied 4.07% to $87.91 on Monday, outperforming its competitors despite a mixed trading session for the broader stock market. The Dow Jones Industrial Average rose while the S&P 500 Index declined. The company's stock closed 36.78% below its 52-week high.
Senseonics Holdings Inc (FRA:6L60) Stock Price, Trades & News
This page provides a comprehensive overview of Senseonics Holdings Inc (FRA:6L60), a medical technology company specializing in continuous glucose monitoring systems. It details the company's current stock price, financial strength, growth, momentum, liquidity, and profitability ranks, along with a business description and upcoming events. The report also highlights three severe warning signs detected by GuruFocus for the stock.
ABT vs. ZBH: Which Surgical Equipment Stock Is the Better Bet Now?
This article compares Abbott (ABT) and Zimmer Biomet (ZBH), two major players in the surgical equipment market, to determine which is a better investment. While Abbott is a larger, more diversified healthcare company, Zimmer Biomet has shown stronger year-to-date performance and more attractive valuation. The analysis suggests that Zimmer Biomet presents a stronger investment case at this time due to rising earnings projections and recent strategic successes.
